^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Voyager-V1

    i
    Other names: Voyager-V1, VSV-IFNbeta-sodium iodide symporter, VSV IFNbeta NIS, VSV-hIFNbeta-NIS, VSV-IFN-NIS, VSV-IFNβ-NIS, recombinant vesicular stomatitis virus-expressing interferon-beta, vesicular stomatitis virus oncolytic virus, VSV oncolytic virus
    Associations

    News

    Trials
    Company:
    Vyriad
    Drug class:
    IFNβ stimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Vyriad, Inc. | Recruiting --> Active, not recruiting | N=86 --> 33 | Trial completion date: Dec 2025 --> Sep 2025 | Trial primary completion date: Dec 2025 --> Jul 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    3ms
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2025 --> Jan 2028
    Trial completion date
    |
    Jakafi (ruxolitinib) • Voyager-V1
    5ms
    Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Trial completion
    |
    sorafenib • Voyager-V1
    8ms
    Phase 2 Trial of Voyager V1 in Combination with Cemiplimab in Cancer Patients (clinicaltrials.gov)
    P2, N=87, Recruiting, Vyriad, Inc. | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • Voyager-V1
    11ms
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=86, Recruiting, Vyriad, Inc. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    over1year
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jun 2024 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Jakafi (ruxolitinib) • Voyager-V1
    over1year
    Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1, N=20, Recruiting, Mayo Clinic
    New P1 trial
    |
    Yervoy (ipilimumab) • Libtayo (cemiplimab-rwlc) • Voyager-V1
    over1year
    Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients (clinicaltrials.gov)
    P2, N=87, Recruiting, Vyriad, Inc. | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600
    |
    Libtayo (cemiplimab-rwlc) • Voyager-V1
    over1year
    Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (clinicaltrials.gov)
    P1/2, N=70, Recruiting, Vyriad, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition
    |
    PD-L1 (Programmed death ligand 1) • IFNB1 (Interferon Beta 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • Voyager-V1
    over1year
    VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov)
    P1, N=120, Recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Apr 2032 | Trial primary completion date: Dec 2024 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Jakafi (ruxolitinib) • cyclophosphamide • Libtayo (cemiplimab-rwlc) • Voyager-V1
    almost2years
    VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=77 --> 34
    Enrollment closed • Enrollment change • Metastases
    |
    Jakafi (ruxolitinib) • Voyager-V1
    almost2years
    Phase 1/2 trial of vesicular stomatitis virus expressing human interferon-β and NIS (VSV-IFNβ-NIS), with ipilimumab and nivolumab, in patients with neuroendocrine carcinoma. (ASCO-GI 2024)
    The optimal systemic therapy beyond first line platinum and etoposide is not established...If at least one objective response is observed, and safety is confirmed, the regimen will be considered for future study. Clinical trial information: NCT03647163.
    Clinical • P1/2 data
    |
    IFNB1 (Interferon Beta 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • etoposide IV • Voyager-V1